Development and Validation of a Serum Biomarker for the Diagnostic Work-up of Asthma
NCT ID: NCT04377958
Last Updated: 2020-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
117 participants
INTERVENTIONAL
2016-12-31
2020-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 2
NCT01224951
Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy
NCT05270278
Biomarkers in Exhaled Breath From Asthmatic Patients
NCT00635271
Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers
NCT02537691
Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 3
NCT01224964
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Asthmatics
Asthmatic group from which serum samples will be collected for analysis
Serum biomarker testing
Serum and sputum samples will be collected and biomarkers will be evaluated using ELISA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serum biomarker testing
Serum and sputum samples will be collected and biomarkers will be evaluated using ELISA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* physician-diagnosed asthma
Exclusion Criteria
* Presence of other pulmonary diseases (Chronic obstructive pulmonary disease, alfa-1-antitrypsine deficiency emphysema, Immunoglobulin E deficiency, allergic bronchopulmonary aspergillosis)
* \> 15 pack years
* No sputum available
* Respiratory infection
* Other inflammatory diseases (Rheumatoid Arthritis, Colitis Ulcerosa)
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tatjana Decaesteker
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lieven Dupont
Role: PRINCIPAL_INVESTIGATOR
UZ Leuven
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
s52549
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.